There are currently 64 clinical trials in Macon, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical Center of Central Georgia, Central Georgia Gynecologic Oncology, GSK Investigational Site and Gastroenterology Associates of Central Georgia, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
NCT05238142
Recruiting
The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes in a home setting. The combined run-in period and study period will be approximately 135 days long.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/28/2024
Locations: East Coast Institute for Research, Macon, Georgia
Conditions: Type 2 Diabetes Treated With Insulin
Register for Updates
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
NCT05263206
Recruiting
The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design may be adapted based on the results of Study A. For both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (wor... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/27/2024
Locations: Skin Care Physicians of Georgia Site Number : 8400030, Macon, Georgia
Conditions: Pruritus
Register for Updates
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease.
Gender:
All
Ages:
45 years and above
Trial Updated:
05/27/2024
Locations: East Coast Institute for Research, LLC, Macon, Georgia
Conditions: Overweight and Obesity
Register for Updates
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: East Coast Institute for Research at The Jones Center, Macon, Georgia
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to <6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of th... Read More
Gender:
All
Ages:
Between 6 months and 5 years
Trial Updated:
05/24/2024
Locations: Meridian Clinical Research, Macon, Georgia
Conditions: SARS-CoV-2
Register for Updates
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin al... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/22/2024
Locations: Research Site, Macon, Georgia
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544
Recruiting
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Skin Care Physicians of Georgia, Macon, Georgia
Conditions: Plaque Psoriasis
Register for Updates
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935
Recruiting
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
05/09/2024
Locations: Gastroenterology Associates Of Central Georgia LLC, Macon, Georgia
Conditions: Eosinophilic Esophagitis
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Northside Hospital,308 Coliseum Dr., Macon, Georgia
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
NCT06358950
Recruiting
The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/07/2024
Locations: Alkermes Investigational Site, Macon, Georgia
Conditions: Narcolepsy Type 1
Register for Updates
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT05570006
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective ABBV-668 is in treating adult participants with UC. Adverse events and change in disease activity will be assessed. ABBV-668 is an investigational drug being developed for the treatment of moderate to severe UC. Approximately 40 adult participants diagnosed with UC will be enrolled in approx... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Gastroenterology Associates of Central Georgia, LLC /ID# 249278, Macon, Georgia
Conditions: Ulcerative Colitis
Register for Updates
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
NCT05561127
Recruiting
To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.
Gender:
All
Ages:
22 years and above
Trial Updated:
04/30/2024
Locations: Gastroenterology Associates of Central Georgia, LLC, Macon, Georgia
Conditions: Bowel; Stricture
Register for Updates